Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Comprar returned no results
Showing 181 to 195 of 555 results for compare

  1. Intensive rehabilitation therapies after hip fracture: What is the clinical and cost effectiveness of additional intensive physiotherapy and/or occupational therapy (for example, progressive resistance training) after hip fracture?

    be undertaken. Outcomes should be followed over a minimum of 1 year, and compare if possible, either the recovery curve for restoration...

    Research recommendation
    Published
    3 February 2023

  2. Vascular access devices: skin decontamination:- What is the clinical and cost effectiveness of 2% chlorhexidine in alcohol versus 0.5% chlorhexidine in alcohol versus 2% chlorhexidine aqueous solution versus 0.5% chlorhexidine aqueous solution for cleansing skin (before insertion of peripheral vascular access devices [VADs] and during dressing changes of all VADs) in reducing VAD-related bacteraemia and VAD site infections?

    solutions in the community. A randomised controlled trial is required to compare the clinical and cost effectiveness of the different...

    Research recommendation
    Published
    9 June 2015

  3. Modes of provision of support to healthcare professionals:- What would be the impact of dietetic telephone support to healthcare professionals to aid in the diagnosis and assessment of babies showing non-IgE-mediated food allergy symptoms in primary care and community settings?

    and skills. A community-based randomised controlled trial is needed to compare the standard written dietetic referral method with...

    Research recommendation
    Published
    9 June 2015

  4. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Last updated
    21 May 2024
    View recommendations

    Sections for TA312

  5. Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.

    Technology appraisal guidance
    Published
    23 July 2014
    View recommendations

    Sections for TA316

  6. Maternal request for caesarean birth: What support or psychological interventions would be appropriate for women who have a fear of vaginal childbirth and request a caesarean birth?

    evidence to suggest that any are of benefit. The proposed research would compare in a randomised controlled trial 2 or more of these...

    Research recommendation
    Published
    24 April 2023

  7. Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563)

    Evidence-based recommendations on abemaciclib (Verzenios) for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in adults who have not had endocrine-based therapy before.

    Technology appraisal guidance
    Published
    27 February 2019
    View recommendations

    Sections for TA563

  8. Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease.

    Technology appraisal guidance
    Published
    17 October 2019
    View recommendations

    Sections for TA607

  9. Pharmacological interventions for anxiety disorders in people with learning disabilities who have autism:- What is the clinical and cost effectiveness and safety of pharmacological interventions for anxiety disorders in people with learning disabilities who have autism?

    costs to the NHS.Randomised controlled trials should be carried out to compare the clinical and cost effectiveness of pharmacological...

    Research recommendation
    Published
    17 October 2016

  10. Artificial intelligence (AI)-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images (HTG687)

    Evidence-based recommendations on artificial intelligence (AI)-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images.

    HealthTech guidance
    Published
    5 July 2023
    View recommendations

    Sections for HTG687

  11. For people who have had primary elective shoulder replacement, does self-directed, supervised group or supervised individual rehabilitation produce the most improvement in health-related quality of life 2 years after surgery?

    occupational therapy team. There was no evidence to enable the committee to compare self-directed with supervised outpatient...

    Research recommendation
    Published
    10 August 2020

  12. What are the best ways to support rehabilitation after hip knee or shoulder replacement for people with additional needs (such as people with dementia, a learning difficulty or multiple disabling medical comorbidities)?

    occupational therapy team. There was no evidence to enable the committee to compare self-directed with supervised outpatient...

    Research recommendation
    Published
    10 August 2020

  13. Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)

    Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.

    Technology appraisal guidance
    Published
    24 July 2024

    Sections for TA989

  14. Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1015)

    Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.

    Technology appraisal guidance
    Published
    13 November 2024
    View recommendations

    Sections for TA1015

  15. Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)

    Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    17 April 2019
    View recommendations

    Sections for TA574